06:30 EST Johnson & Johnson to acquire Intra-Cellular (ITCI) for $132.00 per share in cash
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Illumina launches pilot proteomics program with UK Biobank, collaborators
- Johnson & Johnson exploring bid for Intra-Cellular Therapies, Bloomberg reports
- Boston Scientific upgraded to Buy from Hold at Deutsche Bank
- Needham medtech & diagnostics analyst holds analyst/industry conference call
- Johnson & Johnson reports nipocalimab granted FDA Priority Review